New Funding to Support SER-252 Trial in Advanced Parkinson’s
The synthetic cannabinoid Parkinsons trial SER-252 targets levodopa-induced dyskinesia in advanced Parkinson's disease. This novel therapeutic approach could improve management of motor symptoms. Ongoing research aims to validate its clinical efficacy…
Older Adults with COPD Were Prescribed Synthetic Cannabinoids More Often—and at Higher Doses—Than Those Without the Disease
Synthetic oral cannabinoid prescribing is significantly more common among older adults with COPD compared to those without the disease. These patients also receive higher doses and longer treatment durations. Understanding these prescribing patterns is…
Synthetic cannabinoids in Mayotte: High-frequency market evolution example
Synthetic cannabinoid receptor agonists (SCRAs) are rapidly evolving in Mayotte, posing unique clinical challenges. Wastewater-based epidemiology reveals high-frequency market changes. Understanding SCRAs is crucial for managing acute health…
MIRA Pharmaceuticals Reports MIRA-55 Avoids CNS Side Effects
Synthetic cannabinoids CNS side effects have limited clinical use of many compounds. MIRA Pharmaceuticals reports MIRA-55 shows no THC- or rimonabant-associated CNS side effects in preclinical studies. This research could advance cannabinoid drug…
Many Hemp Intoxicants Contain THC and Synthetic Cannabinoids – NORML Analysis
Unregulated intoxicating hemp products often contain delta-9 THC above legal limits and synthetic cannabinoids. These products pose significant health risks due to unpredictable potency and lack of labeling. Consumers should be aware of the dangers…
Synthetic Cannabinoid Ajulemic Acid Shows Potent Antifibrotic Effects in Systemic Sclerosis Models
Ajulemic acid antifibrotic effects have shown promise in reducing collagen synthesis in systemic sclerosis models. This synthetic cannabinoid activates PPAR-γ to inhibit fibrogenesis. Research supports its potential as a treatment for scleroderma-related…
The synthetic cannabinoid WIN55,212-2 mesylate decreases inflammatory mediators in rheumatoid arthritis synovial fibroblasts
The synthetic cannabinoid WIN55212-2 mesylate plays a significant role in reducing inflammatory mediators in rheumatoid arthritis synovial fibroblasts. This compound modulates immune cell activity to protect joint tissues. Understanding its mechanisms…
Synthetic cannabinoids cause more convulsion and hypothermia in mice than cannabis-derived cannabinoids.
Synthetic cannabinoids toxicity causes more convulsions and hypothermia in mice than cannabis-derived cannabinoids. This study compares effects of synthetic and endogenous cannabinoids on biological systems. Findings reveal synthetic cannabinoids…